Stocks

Headlines

AMGN Insider Selling Amidst Mixed Hedge Fund Activity

AMGN sees significant insider selling, raising concerns among investors. The EVP & General Counsel sold a large number of shares, while hedge fund activities illustrate a split in sentiment.

Date: 
AI Rating:   5
Insider Trading Activity: The latest report indicates that Jonathan P Graham, the EVP & General Counsel of AMGN, sold 25,045 shares valued at approximately $7,341,122, which is around 46.4% of his holdings in this class of stock. Following this transaction, he still possesses 28,987 shares, suggesting a significant reduction in his stake. Another insider, Nancy A. Grygiel, also sold 1,589 shares for around $483,807. The fact that there have been two sales and no purchases by insiders over the last 6 months may imply a lack of confidence among AMGN insiders in the company's stock performance at this time.

Hedge Fund Activity: There were 1,165 institutional investors adding shares of AMGN, while 1,369 decreased their positions in the latest quarter. This uneven trend may indicate mixed feelings from institutional investors. The notable decrease in shares by Pathway Financial Advisers (-99.7%), Bank of America Corp (-28.7%), and PRIMECAP Management Co (-8.8%) could create further uncertainty among investors, particularly as these actions reflect a withdrawal of significant institutional investment. Conversely, Charles Schwab Investment Management added shares, which showcases that some investors retain confidence in AMGN's potential.

Congressional Stock Trading: Congressman transactions show minimal activity as well, with one purchase and one sale in the last six months. Representative Virginia Foxx purchased AMGN stock for up to $15,000, while Senator Sheldon Whitehouse sold an equivalent amount. This limited trading by members of Congress further emphasizes the cautious sentiment surrounding AMGN's market performance.

Overall, the insider and institutional trading trends suggest a potential decrease in AMGN's stock price due to heightened skepticism among key stakeholders regarding the company's future prospects.
Stocks:  AMGN